Genzyme Corporation (NASDAQ: GENZ) is a biotechnology company based in Cambridge, Massachusetts. Genzyme is the world’s third biggest biotechnology company employing over 9,000 people around the world. At present, the company has approximately 80 locations in 40 countries. It includes 17 manufacturing facilities and 9 genetic testing laboratories. The company’s products are available in nearly 90 countries. In 2006, Genzyme generated $3.2 billion in revenues with more than 25 products in the world’s markets. The company is also involved in philanthropic acts, donating $83 million in global product donations and $11 million in cash contributions in 2006. In 2006 and 2007 Genzyme was named one of Fortune Magazine’s “100 Best Companies to Work for.” Additionally in 2007, Genzyme was awarded the National Medal of Technology, the highest level of honor awarded by the President of the United States to America’s leading innovators. NASDAQ in Times Square, New York City. ... Location in Massachusetts Coordinates: , Country United States State Massachusetts County Middlesex County Settled 1630 Incorporated 1636 Government  - Type Mayor-council city  - Mayor Kenneth Reeves (D) Area  - City  7. ... Categories: Magazines stubs | Time Warner subsidiaries | Business magazines ... The National Medal of Technology is an honor granted by the President of the United States to inventors and innovators that have made significant contributions to the development of new and important technology. ...

The company, started by a small group of scientists in 1981, was primarily devoted to finding drugs that would cure enzyme deficiency conditions that were essential to one’s survival and which usually afflict a very small percentage of the world’s population. Drugs used to treat such conditions are termed “orphan drugs.” In 1986, the company went public raising $27 million. An orphan drug is any drug developed under the 1983 U.S. Orphan Drug Act, which concerns drugs for orphan diseases, namely such affecting less than 200,000 people in the US. This has been adopted as a subclause of the FDA. Developing a drug for groups that small would...

Genzyme focuses on six areas of medicine relating to lysosomal storage diseases, renal disease, orthopedics, transplant and immune diseases, oncology, genetics and diagnostics. The first orphan-drug for Genzyme that FDA approved was Ceredase, a drug for treating Gaucher disease. Other important drugs made by Genzyme are Renagel, used in treatment of dialysis patients, and Fabrazyme, used to treat patients with Fabry's disease. Other products in development are Tolevamer for Clostridium dificile colitis disease and Campath for multiple sclerosis. The lysosomal storage diseases are a group of over thirty disorders that result from defects in lysosomal function. ... Kidneys viewed from behind with spine removed The kidneys are bean-shaped excretory organs in vertebrates. ... Orthopedic surgery or orthopedics (BE: orthopaedics) is the branch of surgery concerned with acute, chronic, traumatic and recurrent injuries and other disorders of the locomotor system, its musclular and bone parts. ... Oncology is the branch of medicine that studies tumors (cancer) and seeks to understand their development, diagnosis, treatment, and prevention. ... Alglucerase is a modified form of human β-glucocerebrosidase where the non-reducing ends of the oligosaccharide chains have been terminated with mannose residues. ... In medicine (hematology), Gauchers disease (or Gaucher disease) is a genetic disorder that affects white blood cells, the spleen, bones and brain. ... Sevelamer (rINN) (IPA: ) is a phosphate binding drug used to prevent hyperphosphataemia in patients with chronic renal failure. ... Fabry disease (also known as Anderson-Fabry disease, Angiokeratoma corporis diffusum, Ceramide trihexosidosis, and Sweeley-Klionsky disease) is an X-linked recessive inherited lysosomal storage disease. ... Alemtuzumab (marketed as Campath or Campath-1H) is a monoclonal antibody used in the treatment of chronic lymphocytic leukemia (CLL) and T-cell lymphoma. ...

Genzyme has a sub-license from Bioenvision to market Clofarabine in North America. Bioenvision has the rights to Clofarabine in the rest of the world. On Tuesday, May 29, 2007 Genzyme made a tender offer to purchase Bioenvision for $5.60 per share. Bioenvision management and the board of directors tendered their shares via an agreement prior to the announcement. However, not many other shareholders did and the tender offer closed without Genzyme acquiring their necessary 51% of Bioenvision. It remains to be seen if Genzyme will just be a shareholder of Bioenvision or proceed with a higher subsequent offer. Clofarabine: chemical structure Clofarabine is a substance that is being studied in the treatment of cancer. ...

In 2006, CEO, President, and Board Chairman Henri Termeer, earned a salary of $1.4 million, and non-cash compensation worth $21 million.^[1]

References

• Schouten, E. "Genzyme’s lifelong commitments". NRC Handelsblad. November 24, 2005.
• http://www.gaucher.org.uk/cercer.htm)
• Hirehealth’s website (http://www.hirehealth.com/Public/CompanyDetails.aspx?COMPANY_ID=44719)
• Riskind. P. Multiple Sclerosis—The immune system’s terrible mistake. Fall 1996, Vo. 5, No. 4.
• Hoovers’ website (http://www.hoovers.com/genzyme/--ID__13560--/free-co-factsheet.xhtml)
• Calabro, S. "Genzyme put patients first, and grew to become a multi-billion-dollar company. But empires don't survive on altruism." Pharmaceutical Executive, [March 1, 2006] (http://www.pharmexec.com/pharmexec/article/articleDetail.jsp?id=310976&&pageID=7&searchString=genzyme)

is the 328th day of the year (329th in leap years) in the Gregorian calendar. ... Year 2005 (MMV) was a common year starting on Saturday (link displays full calendar) of the Gregorian calendar. ...

External links

• Genzyme corporate website